Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Caremark To Join Medco In Applying To Be National Medicare Rx Sponsor

This article was originally published in The Pink Sheet Daily

Executive Summary

Assuming both PBMs are approved as national Part D sponsors, there will be no need for “fallback” plans in 2006. Caremark, like Medco, is stressing a desire to sell Part D through health plan and employer clients.
Advertisement

Related Content

CMS Has “Very Robust” Number Of Medicare Part D Bids, McClellan Says
Caremark May Offer "Open" Medicare Rx Plan In Some Regions
Caremark Anticipates Modest Uptake For Medicare Rx Benefit In 2006
Ovations Seeks To Be National Medicare Drug Plan Sponsor
Aetna Members To Exclusively Use Specialty Pharmacy Joint Venture By October
Aetna Seeks To Serve As National Rx Drug Plan Under Medicare Part D
Express Scripts Will Be Medicare PDP, But Only To Support Employer Clients
Medco Plans National Medicare Rx Presence: At Risk But Invisible
Medco Plans National Medicare Rx Presence: At Risk But Invisible
Medicare Stand-Alone Rx Plans Will Be Available "Everywhere," McClellan Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS061561

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel